ATE389724T1 - Menschliche dnase i hyperaktive varianten - Google Patents

Menschliche dnase i hyperaktive varianten

Info

Publication number
ATE389724T1
ATE389724T1 AT97929686T AT97929686T ATE389724T1 AT E389724 T1 ATE389724 T1 AT E389724T1 AT 97929686 T AT97929686 T AT 97929686T AT 97929686 T AT97929686 T AT 97929686T AT E389724 T1 ATE389724 T1 AT E389724T1
Authority
AT
Austria
Prior art keywords
variants
human dnase
hyperactive
hyperactive variants
relates
Prior art date
Application number
AT97929686T
Other languages
English (en)
Inventor
Robert LAZARUS
Clark Pan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE389724T1 publication Critical patent/ATE389724T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97929686T 1996-06-14 1997-06-09 Menschliche dnase i hyperaktive varianten ATE389724T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/663,831 US6391607B1 (en) 1996-06-14 1996-06-14 Human DNase I hyperactive variants

Publications (1)

Publication Number Publication Date
ATE389724T1 true ATE389724T1 (de) 2008-04-15

Family

ID=24663430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929686T ATE389724T1 (de) 1996-06-14 1997-06-09 Menschliche dnase i hyperaktive varianten

Country Status (12)

Country Link
US (4) US6391607B1 (de)
EP (1) EP0910647B1 (de)
JP (1) JP3468778B2 (de)
AT (1) ATE389724T1 (de)
AU (1) AU737618B2 (de)
CA (1) CA2257133C (de)
DE (1) DE69738581T2 (de)
DK (1) DK0910647T3 (de)
ES (1) ES2301180T3 (de)
NZ (1) NZ333128A (de)
PT (1) PT910647E (de)
WO (1) WO1997047751A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
AU2002255736B2 (en) * 2001-03-15 2006-08-31 Regenerx, Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US20050016668A1 (en) * 2003-06-16 2005-01-27 Lori Powers Method and apparatus for cutting through an outer layer on a container
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
RU2269358C2 (ru) * 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
WO2005007187A1 (fr) * 2003-07-14 2005-01-27 Viktor Veniaminovich Tets Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l'efficacite du traitement, agents et compositions pharmaceutiques associes
JP2007532666A (ja) * 2004-04-14 2007-11-15 アヴィリッド インコーポレーテッド ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
PL2086642T3 (pl) 2006-10-18 2015-02-27 Periness Ltd DNaza do leczenia męskiej subpłodności
ATE513557T1 (de) * 2006-11-28 2011-07-15 Cls Therapeutics Ltd Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens
CA2757951A1 (en) * 2009-04-10 2010-10-14 Biorad Laboratories, Inc. Modified dnase compositions and methods of use thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
IL297588A (en) 2009-11-02 2022-12-01 Univ Washington Therapeutic nuclease preparations and methods
CA3066596A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
EP2468870A1 (de) 2010-12-23 2012-06-27 Philip Morris Products S.A. Verfahren zur Expression von Desoxyribonuklease in Pflanzen
EP2704737B1 (de) 2011-04-29 2018-01-10 University of Washington Therapeutische nukleasezusammensetzungen und verfahren dafür
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
RU2017125957A (ru) * 2015-01-04 2019-02-04 Проталикс Лтд. Модифицированная днказа и ее применения
CN108289932A (zh) 2015-05-22 2018-07-17 D·D·格恩金 胞外dna作为神经变性的治疗靶点
CA2988471A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
US20190241878A1 (en) 2016-07-01 2019-08-08 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
JP2019530463A (ja) 2016-10-13 2019-10-24 ユニバーシティ オブ マサチューセッツ Ａａｖカプシド設計
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
EP3351263A1 (de) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmazeutische zusammensetzung zur behandlung oder prävention von gewebeadhäsion
CA3073317A1 (en) 2017-08-18 2019-02-21 Neutrolis Therapeutics, Inc. Engineered dnase enzymes and use in therapy
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
KR20210113261A (ko) 2019-01-04 2021-09-15 리졸브 테라퓨틱스, 엘엘씨 뉴클레아제 융합 단백질을 사용한 쇼그렌병의 치료
EP4055156A2 (de) * 2019-11-08 2022-09-14 Thermo Fisher Scientific Baltics Uab Desoxyribonuklease-varianten und verwendungen davon
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
JP2023545740A (ja) 2020-10-07 2023-10-31 プロタリクス リミテッド 長期活性ＤＮａｓｅ
WO2022178090A2 (en) 2021-02-19 2022-08-25 Theripion, Inc. Dnase fusion polypeptides and related compositions and methods
US11993792B2 (en) 2021-05-27 2024-05-28 New England Biolabs, Inc. DNase I variants, compositions, methods, and kits

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929551T2 (de) 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
JP4077873B2 (ja) 1992-11-02 2008-04-23 ジェネンテック・インコーポレーテッド 呼吸器病治療の査定用コンパクション検定
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
BR9510323A (pt) 1995-02-24 1997-11-11 Genentech Inc Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants

Also Published As

Publication number Publication date
DE69738581T2 (de) 2009-04-23
US7407785B2 (en) 2008-08-05
WO1997047751A1 (en) 1997-12-18
US6391607B1 (en) 2002-05-21
CA2257133C (en) 2008-01-22
US20050170365A1 (en) 2005-08-04
CA2257133A1 (en) 1997-12-18
EP0910647B1 (de) 2008-03-19
ES2301180T3 (es) 2008-06-16
US20080293121A1 (en) 2008-11-27
JP3468778B2 (ja) 2003-11-17
JP2000512496A (ja) 2000-09-26
DE69738581D1 (de) 2008-04-30
DK0910647T3 (da) 2008-07-21
NZ333128A (en) 2000-08-25
US20020173025A1 (en) 2002-11-21
EP0910647A1 (de) 1999-04-28
AU737618B2 (en) 2001-08-23
PT910647E (pt) 2008-04-15
AU3368497A (en) 1998-01-07

Similar Documents

Publication Publication Date Title
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
ATE330967T1 (de) An her2 bindende peptidverbindungen
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE69718734D1 (de) Bicyclische aromatische verbindungen
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
DE69529235T2 (de) Menschliche dnase i varianten
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
ATE278011T1 (de) Human dnase ii
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
MX9706429A (es) Variantes de dnasa i humana.
ATE224730T1 (de) Mittel zur behandlung von pigmentierungsstörungen
UA81601C2 (ru) Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0910647

Country of ref document: EP